C-Jun N-terminal kinase contributes to norepinephrine-induced contraction through phosphorylation of caldesmon in rat aortic smooth muscle

Journal of Pharmacological Sciences

Volumn 100, Issue 2, 2006, Pages 119-125

  Youn, Ri Lee ^a   Lee, Chang Kwon ^a   Park, Hyo Jun ^a   Kim, Hyojin ^a   Kim, Junghwan ^a   Kim, Jaeheung ^a   Keun, Sang Lee ^a   Yun, Lyul Lee ^b   Kyung, Ok Min ^c   Kim, Bokyung ^a  

^a Konkuk University   (South Korea)

^b Hallym University   (South Korea)

^c Yongin University   (South Korea)

Author keywords

C Jun N terminal kinase; Caldesmon; Hypertension; Mitogen activated protein kinase; Vascular smooth muscle contraction

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CALDESMON; ENZYME INHIBITOR; NORADRENALIN; PROTEIN KINASE C; RHO KINASE; STRESS ACTIVATED PROTEIN KINASE; THYMELEATOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA MEDIA; ARTICLE; CONCENTRATION RESPONSE; DRUG SELECTIVITY; HYPERTENSION; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

EID: 33244469244     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0050777     Document Type: Article

References (23)

1. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano K, Harada K, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev. 1997;49:157-230.
2. Kim B, Kim J, Bae YM, Cho SI, Kwon SC, Jung JY, et al. p38 MAPK contributes to the diminished aortic contraction by ET-1 in DOCA-salt hypertensive rats. Hypertension. 2004;43:1086-1091.
3. Bi D, Nishimura J, Niiro N, Hirano K, Kanaide H. Contractile properties of the cultured vascular smooth muscle cells: the crucial role played by RhoA in the regulation of contractility. Circ Res. 2005;96:890-897.
4. Miyata Y, Nishida E. Distantly related cousins of MAP kinase: biochemical properties and possible physiological functions. Biochem Biophys Res Commun. 1999;266:291-295.
5. Dessy C, Kim I, Sougnez CL, Laporte R, Morgan KG. A role for MAP kinase in differentiated smooth muscle contraction evoked by á-adrenoceptor stimulation. Am J Physiol. 1998;275:C1081-C1086.
6. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL. Mitogen-activated protein/ extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res. 1999;84:505-515.
7. Kubo T, Ibusuki T, Saito E, Kambe T, Hagiwara Y. Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats. Eur J Pharmacol. 2000;400:231-237.
8. Kim J, Lee YR, Lee CH, Choi WH, Lee CK, Kim J, et al. Mitogen-activated protein kinase contributes to elevated basal tone in aortic smooth muscle from hypertensive rats. Eur J Pharmacol. 2005;514:209-215.
9. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr Opin Cell Biol. 1998;10:205-219.
10. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature. 2003;424:219-223.
11. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;17:4619-4628.
12. Ioroi T, Yamamori M, Yagi K, Hirai M, Zhan Y, Kim S, et al. Dominant negative c-Jun inhibits platelet-derived growth factordirected migration by vascular smooth muscle cells. J Pharmacol Sci. 2003;91:145-148.
13. Vaishnav D, Jambal P, Reusch JE, Pugazhenthi S. SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway. Biochem Biophys Res Commun. 2003;307:855-860.
14. Bachar O, Adner M, Uddman R, Cardell LO. Toll-like receptor stimulation induces airway hyper-responsiveness to bradykinin, an effect mediated by JNK and NF-κB signaling pathways. Eur J Immunol. 2004;34:1196-1207.
15. Watts SW. 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension. 2000;35:244-248.
16. Kim B, Kim J, Kim A, Kim YS, Lee YR, Bae YM, et al. Ligusticum wallichi-induced vasorelaxation mediated by mitogen-activated protein kinase in rat aortic smooth muscle. J Ethnopharmacol. 2004;90:397-401.
17. Northcott C, Florian JA, Dorrance, A, Watts SW. Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension. 2001;38:1337-1341.
18. Banes A, Florian JA, Watts SW. Mechanisms of 5-hydroxytryptamine( 2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther. 1999;291:1179-1187.
19. Zhao Y, Zhang L, Longo LD. PKC-induced ERK1/2 interactions and downstream effectors in ovine cerebral arteries. Am J Physiol. 2005;289:R164-R171.
20. 2+-independent contractions of vascular smooth muscle. Biochem Cell Biol. 1996;74:485-502.
21. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995;9:484-496.
22. Kim B, Kim YS, Ahn J, Kim J, Cho SI, Won KJ, et al. Conventional-type protein kinase C contributes to phorbol ester-induced inhibition of rat myometrial tension. Br J Pharmacol. 2003;139:408-414.
23. Kwon S, Fang LH, Kim B, Ha TS, Lee SJ, Ahn HY. p38 Mitogen-activated protein kinase regulates vasoconstriction in spontaneously hypertensive rats. J Pharmacol Sci. 2004;95:267-272.